Connor Clark & Lunn Investment Management Ltd. Increases Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 71.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 711,278 shares of the biopharmaceutical company’s stock after buying an additional 295,378 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned about 0.36% of Esperion Therapeutics worth $1,174,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of Esperion Therapeutics by 71.8% in the 1st quarter. Vanguard Group Inc. now owns 8,826,546 shares of the biopharmaceutical company’s stock worth $23,655,000 after purchasing an additional 3,688,796 shares in the last quarter. Marshall Wace LLP increased its stake in shares of Esperion Therapeutics by 94.2% in the 2nd quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company’s stock worth $9,554,000 after purchasing an additional 2,087,635 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Esperion Therapeutics by 3,278.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 572,323 shares of the biopharmaceutical company’s stock worth $1,271,000 after purchasing an additional 555,382 shares in the last quarter. XTX Topco Ltd increased its stake in shares of Esperion Therapeutics by 751.6% in the 2nd quarter. XTX Topco Ltd now owns 364,681 shares of the biopharmaceutical company’s stock worth $810,000 after purchasing an additional 321,859 shares in the last quarter. Finally, Inspire Investing LLC purchased a new stake in shares of Esperion Therapeutics in the 2nd quarter worth $758,000. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ESPR. Needham & Company LLC reduced their price objective on Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, August 13th. StockNews.com lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, HC Wainwright restated a “buy” rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a research note on Wednesday.

Esperion Therapeutics Stock Performance

Shares of Esperion Therapeutics stock opened at $2.54 on Thursday. The company has a market capitalization of $500.48 million, a P/E ratio of -3.97 and a beta of 0.96. The company has a fifty day moving average of $2.08 and a 200 day moving average of $2.16. Esperion Therapeutics, Inc. has a fifty-two week low of $1.16 and a fifty-two week high of $3.40.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.